This study aims to determine whether higher or lower expression of Cdk5 levels in the blood of AD and Mild Cognitive Impairment (MCI) patients is associated with an increased risk of cognitive decline by correlating with Mcl1 level. Here, MCL1 is linked to Cognitive impairment.